Match Document Document Title
US20170029437 Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders  
The invention features compositions and methods for treating or preventing a neoplasia. More specifically, the invention provides compositions and methods for disrupting the interaction of a BET...
US20160193152 METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS  
Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the...
US20160038508 PHARMACEUTICAL COMPOSITIONS COMPRISING SORBITAN ESTERS  
The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.
US20160022574 NON-MUCOADHESIVE FILM DOSAGE FORMS  
Orally disintegrating film dosage forms for delivering active pharmaceutical agents, methods of formulating the dosage forms to retard absorption through the oral mucosa, and methods of using the...
US20150224130 Solid Carriers for Improved Delivery of Active Ingredients in Pharmaceutical Compositions  
The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one...
US20150064118 LIPID DEPOT FORMULATIONS  
The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least...
US20140107107 PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS  
A solid dispersion comprising an amorphous thienotriazolodiazepine compound of the Formula (1) wherein X is a halogen, R1 is C1-C4 alkyl, R2 is C1-C4 alkyl, a is an integer of 1-4, R3 is C1-C4...
US20130236573 ESKETAMINE FOR THE TREATMENT OF TREATMENT-REFRACTORY OR TREATMENT-RESISTANT DEPRESSION  
The present invention is directed to methods for the treatment of treatment-refractory depression or treatment-resistant depression comprising administering to a patient in need thereof, a...
US20110300210 CONTROLLED RELEASE NANOPARTICULATE CLOZAPINE COMPOSITIONS  
Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the...
US20100260858 DRUG DELIVERY COMPOSITION  
A composition for delivery of a drug is disclosed. The composition has a semipermeable coating, particles of a medicament having an effective average particle size of less than or about 2 μm and...
US20100063010 METHOD FOR ADMINISTERING A SPILL RESISTANT PHARMACEUTICAL SYSTEM  
A method for administering a spill-resistant pharmaceutical formulation comprises delivery from a squeezable container of a pharmaceutical agent in a suitable vehicle comprising a liquid base and...
US20090297619 NANOPARTICULATE ANTICONVULSANT AND IMMUNOSUPPRESSIVE COMPOSITIONS  
Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the...
US20080248123 Nanoparticulate anticonvulsant and immunosuppressive compositions  
Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the...
US20070105843 COMBINATION OF A SEROTONIN REUPTAKE INHIBITOR AND A 5-HT2C ANTAGONIST, INVERSE AGONIST OR PARTIAL AGONIST  
The present invention relates to the use of compounds and compositions of compounds having serotonin reuptake inhibiting activity and 5-HT2C antagonistic, partial agonistic or inverse agonistic...
US20060111307 Methods and compositions for treating pain  
Methods and compositions are described for the modulation of central nervous system and/or fetal effects of substances. Methods and compositions are described for the modulation of efflux...
US20050119160 Methods and reagents for the treatment of immunoinflammatory disorders  
The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient a tetra-substituted...
US20050014743 Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders  
The present invention provides a method for the treatment of depression, including treatment-resistant depression, and other mood disorders using a combination of an NMDA receptor antagonist and a...
US20160045504 COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA  
The invention relates generally to effective treatment leukemia. In particular, the present invention provides compositions and methods to inhibit the interaction of menin with MLL and MLL-fusion...
US20150283092 DRUG DELIVERY COMPOSITION  
A composition for delivery of a drug is disclosed. The composition has a semipermeable coating, particles of a medicament having an effective average particle size of less than or about 2 μm and...
US20150210706 Benzodiazepine Bromodomain Inhibitor  
The present invention relates to a benzodiazepine compound, processes for its preparation, pharmaceutical compositions containing such a compound and to its use in therapy.
US20140206667 METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA  
The invention relates to methods and compositions for treating schizophrenia or bipolar disorder (in particular, mania) by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and...
US20140051689 Polycyclic Agents for the Treatment of Respiratory Syncytial Virus Infections  
Compounds of formula (I), and their use as in the treatment of infections involving viruses of the Pneumovirinae sub-family (RSV) are disclosed. In the formula ring (A) may be phenyl, pyridyl...
US20140038935 DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES  
The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of...
US20120003330 BENZOQUINOLONE INHIBITORS OF VMAT2  
The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof.
US20100260859 CONTROLLED-RELEASE CLOZAPINE COMPOSITIONS  
A composition for delivery of a drug is disclosed. The composition has a semipermeable coating, particles of clozapine having an effective average particle size of less than or about 2 μm and at...
US20100189762 TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS  
Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and...
US20090186099 BUCCAL, POLAR AND NON-POLAR SPRAY OR CAPSULE CONTAINING DRUGS FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM  
Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in...
US20090018119 USE OF N-DESMETHYLCLOZAPINE TO TREAT HUMAN NEUROPSYCHIATRIC DISEASE  
Disclosed herein is a method to treat neuropsychiatric diseases including psychosis, affective disorders, dementia, neuropathic pain, and glaucoma. Treatment is carried out by administering a...
US20070219243 Method for improving the pharmacokinetics of HIV integrase inhibitors  
The invention provides methods for improving the pharmacokinetics of an HIV integrase inhibiting compound by administering food and/or ritonavir or a pharmaceutically acceptable salt thereof with...
US20060276412 METHODS AND COMPOSITIONS FOR MANAGING PSYCHOTIC DISORDERS  
Compositions for treating psychotic disorders comprise a first ingredient and a second ingredient, wherein the first ingredient comprises at least one antipsychotic agent selected from the group...
US20060069086 Methods for regulating neurotransmitter systems by inducing counteradaptations  
The present invention relates to methods for regulating neurotransmitter systems by inducing a counteradaptation response. According to one embodiment of the invention, a method for regulating a...
US20050181049 Composition and method for enhancing bioavailability  
The present invention relates to compositions and methods for enhancing the bioavailability of beneficial agents with low water solubility.
US20170166562 BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2  
The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof.
US20170145021 NOVEL COMPOUNDS  
Benzodiazepine compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.
US20160158220 BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2  
The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof.
US20140128378 METHODS OF TREATING EPILEPTOGENESIS  
The present invention is directed to the use of a class of peptide Compounds for prevention, alleviation or/and treatment of refractory Status epilepticus.
US20120027879 BUCCAL, POLAR AND NON-POLAR SPRAY OR CAPSULE CONTAINING DRUGS FOR TREATING METABOLIC DISORDERS  
Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in...
US20110046117 COMPOSITIONS OF 5-HT3 ANTAGONISTS AND DOPAMINE D2 ANTAGONISTS FOR TREATMENT OF DOPAMINE-ASSOCIATED CHRONIC CONDITIONS  
The present invention provides novel compositions comprising a combination of a 5-HT3 receptor antagonist and a selective dopamine D2 receptor antagonist for the treatment of alcohol dependence...
US20100113427 COMPOSITIONS OF 5-HT3 ANTAGONISTS AND DOPAMINE D2 ANTAGONISTS FOR TREATMENT OF DOPAMINE-ASSOCIATED CHRONIC CONDITIONS  
The present invention provides novel compositions comprising a combination of a 5-HT3 receptor antagonist and a selective dopamine D2 receptor antagonist for the treatment of alcohol dependence...
US20100113426 Intranasal Benzodiazepine Compositions  
A pharmaceutical composition for intranasal administration to a mammal. The pharmaceutical composition comprises an effective amount of a benzodiazepine or pharmaceutically acceptable salt...
US20080004260 Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions  
The present invention provides novel compositions comprising a combination of a 5-HT3 receptor antagonist and a selective dopamine D2 receptor antagonist for the treatment of alcohol dependence...
US20070172469 Methods For Inhibiting Viral Replication In Vivo  
The present invention is directed to methods of modulating viral replication in vivo comprising administering to an individual a therapeutically or prophylactically effective amount of a...
US20070160668 Prolonged release bioadhesive therapeutic systems  
The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active principle dissolution test of more than 70% over...
US20070087977 METHODS AND COMPOSITIONS FOR TREATING PAIN  
Methods and compositions are described for the modulation of central nervous system and/or fetal effects of substances. Methods and compositions are described for the modulation of efflux...
US20060040922 Aripiprazole, olanzapine and haloperidol pamoate salts  
The invention relates to the discovery that pamoate salts of haloperidol and aripiprazole result in a good to superior long acting and/or extended release profile. Thus, in one aspect of the...
US20160346270 BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2  
The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof. (Formula (I))
US20160279141 COMBINATION THERAPY FOR CANCER USING BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEIN INHIBITORS  
The present invention provides methods for treating cancer using combinations of bromodomain and extra-terminal (BET) protein inhibitors and certain chemotherapeutic drugs.
US20160074415 METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT  
The invention relates to methods for preventing, slowing the progression of, delaying or treating metabolic disorders induced in patients by the treatment with neuroleptic agents comprising...
US20160024011 Multi-API Loading Prodrugs  
The present invention accomplishes this by having multiple molecules of parent drugs attached to carrier moieties and by extending the period during which the parent drug is released and absorbed...
US20150164802 Methods for the preparation of biologically active compounds in nanoparticulate form  
A method for producing a composition comprising nanoparticles of a biologically active compound.